Propatyl Nitrate

Summary

Propatyl Nitrate (CHEMBL488280) is a phase-3 clinical-stage small molecule (ATC C01DA07); indicated across 1 condition including cardiovascular disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: C01DA07 (+1 more)
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 269.17 Da · C6H11N3O9

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL488280
Name	Propatyl Nitrate
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	66261
ATC	C01DA07, C01DA57
Molecular formula	C6H11N3O9
Molecular weight	269.17
InChIKey	YZZCJYJBCUJISI-UHFFFAOYSA-N

SMILES: CCC(CO[N+](=O)[O-])(CO[N+](=O)[O-])CO[N+](=O)[O-]

IUPAC name: 2,2-bis(nitrooxymethyl)butyl nitrate

Also known as: Etrynit, ETT-N, ETTN, Propatilnitrato, Propatyl nitrate, Propatylnitrate, WIN 9317, WIN-9317, PROPATYL NITRATE, PROPATYLNITRATE, propatylnitrate

Patent coverage: 1,810 distinct patent families (4,786 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cardiovascular disorder	3	MONDO:0004995	EFO:0000319

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02315976	PHASE4	COMPLETED	Acute Episodes in Chronic Stable Angina: Assessment of the Use of the Coronary Vasodilator Propatyl Nitrate.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).